|
Abnormal behavior
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Patients with SMARCA4 mutations had less coarse craniofacial appearances and behavioral abnormalities.
|
25168959 |
2014 |
|
Abnormal corpus callosum morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of cardiovascular system morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of the clavicle
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of the dentition
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of the hip bone
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of the intervertebral disk
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acute myocardial infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The correlation of the BRG1 rs1122608 single nucleotide polymorphism (SNP) with acute myocardial infarction (AMI) has been reported in American and European populations.
|
29615549 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.
|
26997274 |
2016 |
|
Acute rheumatic heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Bmi1 and BRG1 drive myocardial repair by regulating cardiac stem cell function in acute rheumatic heart disease.
|
29042984 |
2017 |
|
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
SMARCA4-deficient pulmonary adenocarcinoma is emerging as a distinctive, albeit phenotypically heterogeneous molecular subgroup of TTF1-negative NSCLC.
|
28555282 |
2017 |
|
Adenocarcinoma
|
0.060 |
GeneticVariation
|
group |
BEFREE |
We suggest that a mutation in SMARCA4 could be responsible for the transformation of the adenocarcinoma component into the neuroendocrine phenotype.
|
25275049 |
2014 |
|
Adenocarcinoma
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Loss of expression of BRG1 and BRM was frequent in solid predominant adenocarcinomas and tumors with low thyroid transcription factor-1 (TTF-1, master regulator of lung) and low cytokeratin7 and E-cadherin (two markers for bronchial epithelial differentiation).
|
23163725 |
2013 |
|
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
We herein investigated the expression of the SWI/SNF complex catalytic subunits SMARCA4 (BRG1) and SMARCA2 (BRM) in 316 consecutive non-small cell lung cancer (NSCLC) specimens on tissue microarrays (171 adenocarcinomas [ADCAs], 130 squamous cell carcinomas [SCCs], 9 adenosquamous carcinomas, and 6 large cell carcinomas) excluding undifferentiated/giant cell or rhabdoid carcinomas.
|
28038711 |
2017 |
|
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
Our systematic analysis of proteins and glycoproteins demonstrates changes of protein and glycoprotein relative abundance in SqCC (TP53, U2AF1, and RXR) and in ADC (SMARCA4, NOTCH1, PTEN, and MST1).
|
28814946 |
2017 |
|
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
BRG1 and/or BRM protein is absent or disrupted in approximately 17% of all human adenocarcinomas.
|
15887247 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
Biomarker
|
disease |
BEFREE |
A 43-year-old man underwent left upper lobe lung resection and was diagnosed with SMARCA4-deficient lung adenocarcinoma.
|
30972962 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Genetic alterations of the mSWI/SNF chromatin remodeling complexes are the most frequent among chromatin regulators in cancers, with BRG1/SMARCA4 mutations occurring in ∼10-15% of lung adenocarcinomas.
|
24520176 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our study highlights (1) the morphological diversity of SMARCA4-deficient lung adenocarcinoma, (2) the consistent absence of expression of TTF1 in the presence of expression of HepPar-1, (3) absence of EGFR driver mutations, and (4) frequent inactivating SMARCA4 mutations as underlying mechanism of the observed SMARCA4 protein loss.
|
28555282 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
Biomarker
|
disease |
BEFREE |
We conclude that loss of either or both BRG1 and BRM is involved in the progression of lung adenocarcinoma into solid predominant tumors with features of epithelial mesenchymal transition and loss of the bronchial epithelial phenotype.
|
23163725 |
2013 |
|
Adenocarcinoma of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We provide first evidence that Brg1 expression is lost in noninvasive cystic precursor lesions of pancreatic adenocarcinoma.
|
21940037 |
2012 |
|
Adenocarcinoma of small intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
Exome data analysis revealed significantly mutated genes previously linked to SBA (TP53, KRAS, APC, SMAD4, and BRAF), recently reported potential driver genes (SOX9, ATM, and ARID2), as well as novel candidate driver genes, such as ACVR2A, ACVR1B, BRCA2, and SMARCA4.
|
29522538 |
2018 |
|
Adenocarcinoma, Endometrioid
|
0.010 |
Biomarker
|
disease |
BEFREE |
The SMARCA4-intact component was a moderate-to-poorly differentiated endometrioid adenocarcinoma.
|
25920939 |
2015 |
|
Adult Burkitt Lymphoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
BRG1 expression levels could correlate negatively with miR-155 expression levels, at least in Burkitt's lymphoma and diffuse large B cell lymphoma (DLBCL) cell lines.
|
28251496 |
2017 |
|
Adult Burkitt Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In addition, mutations in a number of genes including GNA13, TP53, and SMARCA4 occur in Burkitt lymphoma.
|
24867287 |
2014 |